You are here: Industry Insights > plaque psoriasis

News List

Innovent Announces NMPA Granted New Indication Approvals for SULINNO® (Adalimumab Injection) for the Treatment of Pediatric Plaque Psoriasis and Non-infectious Uveitis prnasia
December 23, 2020
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announces that SULINNO® ...
Henlius Adalimumab Biosimilar Approved by NMPA prnasia
December 09, 2020
Shanghai Henlius Biotech, Inc. announced that the adalimumab biosimilar HLX03, developed and manufactured by the Company independently, has been approved by the National Medical Products Administration (NMPA) for the treatment of rheumatoid arthritis ...
Sun Pharma declares five-year positive results for ILUMYA (tildrakizumab-asmn) expresspharma
November 02, 2020
ILUMYA is approved for adults with moderate-to-severe plaque psoriasis and is being evaluated for other possible uses.
Janssen’s psoriasis med Tremfya scores long-term safety and efficacy data pharmatimes
October 19, 2020
Janssen has announced new open-label extension data for Tremfya, with the treatment continuing to show high rates of skin clearance through nearly five years in moderate to severe plaque psoriasis.
Sun Pharma launches ILUMYA (tildrakizumab) in Japan expresspharma
September 23, 2020
It is indicated for the treatment of plaque psoriasis in adult patients who have an inadequate response to conventional therapies.
Sun Pharma receives Japan MHLW approval of ILUMYATM for the treatment of Plaque Psoriasis expresspharma
June 30, 2020
ILUMYA is one of the key specialty products of Sun Pharma and it was approved by US FDA in March 2018 while the European Commission approved it in September 2018.
Psoriasis digital landscape for patients in Japan offers competent patient engagement: says GlobalDa expresspharma
June 03, 2020
According to GlobalData’s Epidemiology and Market Size Database, the value of the plaque psoriasis market in Japan is estimated to be $627.23m.
Amgen Announces Positive Top-Line Results from Otezla Plaque Psoriasis Study americanpharmaceuticalreview
May 08, 2020
Amgen announced positive top-line results from the ADVANCE trial, a Phase 3, multicenter, randomized, placebo-controlled, double-blind study to assess the efficacy of Otezla® (apremilast) in adults with mild-to-moderate plaque psoriasis.
FDA approves Lilly’s plaque psoriasis drug Taltz for children pharmaceutical-technology
April 01, 2020
The US Food and Drug Administration (FDA) has approved Eli Lilly’s Taltz (ixekizumab) to treat moderate to severe plaque psoriasis in children aged six to below 18 years.
MC2 Therapeutics Announces FDA Acceptance of its New Drug Application for Wynzora™ Cream for Treatment of Plaque Psoriasis b3cnewswire
November 26, 2019
MC2 Therapeutics, an emerging pharmaceutical company focused on novel PAD™ Technology-based topical therapies for chronic inflammatory conditions ...

Previous page 1 2 3 4 Next page